The SLC2A11 antibody targets the solute carrier family 2 member 11 (SLC2A11), a protein encoded by the SLC2A11 gene, which belongs to the glucose transporter (GLUT) family. SLC2A11. also known as GLUT11. facilitates glucose transport across cell membranes and exists in three splice variants (GLUT11A, B, C) with distinct tissue distributions, including heart, muscle, kidney, and adipose tissue. Unlike classical GLUTs, SLC2A11 may also transport fructose and is implicated in metabolic regulation, particularly under low-glucose conditions. Research highlights its role in adipocyte differentiation, insulin resistance, and cancer metabolism, where altered expression correlates with tumor progression and survival.
SLC2A11 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore tissue-specific roles or dysregulation in diseases. Commercially available antibodies vary in specificity, often validated against recombinant proteins or specific isoforms. Challenges include cross-reactivity due to splice variants or homology within the GLUT family. Recent studies using these antibodies suggest SLC2A11 as a potential therapeutic target for metabolic disorders and cancers. However, further validation of antibody specificity and functional studies are needed to fully elucidate its biological and clinical significance.